Checkpoint inhibitor induced hepatitis and the relation with liver metastasis and outcome in advanced melanoma patients.
Maaike BiewengaMonique K van der KooijMichel W J M WoutersMaureen J B AartsFranchette W P J van den BerkmortelJan Willem B de GrootMarye J Boers-SonderenGeke A P HospersDjura PiersmaRozemarijn S van RijnKarijn P M SuijkerbuijkAlbert J Ten TijeAstrid A M van der VeldtGerard VreugdenhilJohn B A G HaanenAlfons J M van der EertweghBart van HoekEllen KapiteijnPublished in: Hepatology international (2021)
Incidence of hepatitis in a real-world cohort is 1.8% for PD-1 inhibitor, 2.6% for ipilimumab and 20.7% for combination therapy. Checkpoint inhibitor-induced hepatitis had no relation with liver metastasis and had no negative effect on the outcome.